Loxapine

General information

Loxapine is a dibenzoxazepine neuroleptic drug.

After 6 and 12 weeks of treatment with loxapine, patients with schizophrenia (n = 24; aged 18–70 years) showed both lymphocyte D2 dopamine-like and 5HT2A platelet receptor binding down-regulation, which suggests that both receptors are involved in the mechanism of action of the drug, as well as possible extrapyramidal adverse reactions [ ].